It has been demonstrated that anti-viral and anti-tumor immunity after PD-1/PD-L1 checkpoint blockade is mediated by the proliferative burst of TCFI+CXCR5+ cells (21, 22, 27–29). Here, CXCR5 is linked to neoplasm.